Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ariana® Pharma and CTCLS Sign Japanese Distribution Agreement

Published: Thursday, November 01, 2012
Last Updated: Thursday, November 01, 2012
Bookmark and Share
Ariana continues global expansion from US to Japan with KEM® data analytics software and services technology.

Ariana Pharma has announced the signing of an exclusive Japanese distribution agreement with CTC Laboratory Systems Corporation (CTCLS), the Japanese supplier of services for R&D solutions.

CTCLS will distribute Ariana’s KEM® data analytics software and services technology to Japanese markets. Ariana selected CTCLS as its Japanese distribution partner because of the company’s dominant presence in Japan.

CTCLS is a leading R&D service provider, offering total solutions to major industries and specializing in the pharmaceutical sector.

Ariana’s KEM®, or Knowledge Extraction and Management, is a novel, association rules-based (non-statistical) data-analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect.

In the life science industry, KEM saves sponsors both time and money by optimizing clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints.

“In the first half of 2012, we expanded west from Europe to launch our US office, and now we’re progressing into the Far East with the CTCLS distribution agreement,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma.

Dr. Afshar continued, “This deal with CTCLS will provide an excellent entry into Asia and the world's third largest biotechnology market. We expect the ongoing growth of Japanese companies in medicine development, diagnostics and biomarker studies will further increase demand for Ariana’s KEM® software.”

“After having invested resources in acquiring equipment and establishing processes to generate data, our clients are now focusing on technologies that extract valuable information and exploit data to the fullest extent,” said Hideki Negishi, president and CEO of CTCLS.

Negishi continued, “CTCLS is selecting leading technologies in pharmaceutical and manufacturing areas to deliver to the Japanese markets. We are confident that the application of KEM will accelerate developments in these industries.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
First 3-D Vision of Cancer Target
This basic research set the grounds for structure-based drug design approaches that could be beneficial for cancer treatments' - Dr. Cyril Dominguez, University of Leicester.
New Light Shed on Genetic Regulation
A team of scientists has uncovered greater intricacy in protein signaling than was previously understood, shedding new light on the nature of genetic production.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!